Search Back New search Go to resultsDiseaseMain groupHematologic NeoplasmsProtocol groupIndolent LymphomasDiseaseNHL, T-cell typeNHL, T-Cell Type, Other Specified Leukemias, Aggressive NK-Cell LeukemiaNHL, T-Cell Type, Peripheral, UnspecifiedSubgroupICD10C84.4C84.5C94.7-MeSHLymphoma, Non-HodgkinLymphoma, T-Cell, PeripheralSequenceChemotherapyChemo-substanceCisplatinDexamethasoneGemcitabinePeg asparaginaseChemo-substanceCisplatinDexamethasoneGemcitabinePeg asparaginaseChemo-substanceCisplatinDexamethasoneGemcitabinePeg asparaginaseChemo-substanceCisplatinDexamethasoneGemcitabinePeg asparaginaseNo. Substances4 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDimetindenFamotidineFosaprepitantGranisetronMagnesium sulfateParacetamolPegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDimetindenFamotidineFosaprepitantGranisetronMagnesium sulfateParacetamolPegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDimetindenFamotidineFosaprepitantGranisetronMagnesium sulfateParacetamolPegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDimetindenFamotidineFosaprepitantGranisetronMagnesium sulfateParacetamolPegfilgrastimPotassium chlorideNo. Substances11Protocol classificationTherapy classificationcurrent standardIntensityStandard doseTherapy indicationFirst lineTherapy phaseTherapy intentioncurativeRisksAnemia Hb below 8g/dlEmetogenicity (MASCC/ESMO)HyperbilirubinemiaIncrease AminotransferasesLeukopeniaNeutropeniaThrombocytopenia below 50 000/µl only studiesPublicationAuthorLi XDiseaseExtranodales NK/T-Zell Lymphom, Stadium III-IV, ErstlinieOriginDepartment of Oncology, The First Affiliated Hospital of Zhengzhou UniversityProtocols in Revision 1 protocol foundProtocols under revision.DDGP (Cisplatin 20 / Gemcitabine 800 / PEG-Asparaginase 2500 / Dexamethasone (7.5/15)), extranodal NK/T-cell Lymphoma (PID2349 V1.0)
